Institute of Cancer & Genetics
Our strategy is to drive research for the benefit of patients affected by cancer and by inherited disease in Wales and beyond, and at all points in the patient pathway - from prevention through screening, diagnosis, imaging, tissue studies, and clinical trials.
The Institute of Cancer & Genetics is a merger of the Institute of Medical Genetics and sections of Oncology, Surgery, Pathology, Haematology, and Gynaecology Oncology.
About us
The Institute of Cancer & Genetics brings together researchers to promote translational research, employing model systems to develop new cancer therapeutics and diagnostics and take them through to the clinic. Covering molecular/cellular biology through to cancer trials there are collaborative links with researchers in the Welsh School of Pharmacy and Cardiff School of Biosciences and also the newly established Cardiff CRUK Cancer Centre. For more information on our research please click here - Cancer Research
News
- February 2012
-
RFC supports gynaecological cancer care
3rd February 2012On Boxing Day 2011, Pontypridd RFC played Cardiff winning 18:13 and supporters attending the match donated a total of £1,040 to help improve patient care in women suffering from gynaecological …
-
RFC supports gynaecological cancer care
- January 2012
-
‘Killer cells’ and diabetes - Cardiff University
16th January 2012Killer T-cells in the human body which help protect us from disease can inadvertently destroy cells that produce insulin, new University research has uncovered. -
Type 1 diabetes discovery by Cardiff University and King's College - www.bbc.co.uk
16th January 2012Scientists say they have uncovered new evidence which it is hoped could eventually help diagnose and prevent type 1 diabetes.
-
‘Killer cells’ and diabetes - Cardiff University
- December 2011
-
Achievement in health innovation - Cardiff University
7th December 2011University scientists have been recognised for innovation in health and social care with awards presented by the First Minister of Wales.
-
Achievement in health innovation - Cardiff University
Publications
- Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.
Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM, Leukemia, Volume 26, 4 (April 2012) pp.826-830 - Expression of CD200 on AML blasts directly suppresses memory T-cell function.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3(+) regulatory T cells.
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, Tonks A, Leukemia (March 2012) - Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C, Clin Cancer Res, Volume 18, 3 (February 2012) pp.678-687 - Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study.
Sharma A, Gentry-Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, Seif MW, Ryan A, Parmar M, Jacobs I, Menon U, UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) None, Bjog, Volume 119, 2 (January 2012) pp.207-219